This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Fragmin® (dalteparin sodium) prescribing information and adverse event reporting can be found at the bottom of the page.

Risk Factors: Thromboprophylaxis in Bedridden Medical Patients

(with medical conditions including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for venous thromboembolism such as age over 75 years, obesity, cancer or previous history of VTE.)

Information on VTE1

  • VTE is a collective term for deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • VTE is a significant cause of mortality, long-term disability and chronic ill-health problems, many of which are avoidable.
  • The incidence of VTE is 1–2 per 1,000 of the population and the risk increases with age.
  • Approximately half of VTE cases are associated with prior hospitalisation for medical illness or surgery.
  • It has been estimated that the management of hospital associated VTE costs the NHS £millions per year.

VTE prevention is an important patient safety issue1

1 in 20 people will have a VTE at some time in their life and approximately half of the cases are associated with prior hospitalisation for medical illness or surgery

VTE causes a larger number of deaths than the combined mortality due to:2

  • Breast cancer
  • HIV
  • Road traffic accidents

VTE is the most common preventable cause of in-hospital death3

General risk factors4**

The general risk factors associated with the development of venous thromboembolism (VTE):

  • Active cancer or cancer treatment
  • Age >60 years
  • Critical care admission
  • Dehydration
  • Known thrombophilias
  • Obesity (body mass index [BMI] >30 kg/m2)
  • One or more significant medical comorbidities (e.g. heart disease; metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)
  • Personal history or first-degree relative with a history of VTE
  • Use of hormone replacement therapy (HRT)
  • Use of oestrogen-containing contraceptive therapy
  • Varicose veins with phlebitis

**For women who are pregnant or have given birth within the previous 6 weeks, please see section 1.16 of NICE NG89.

Bedridden Thromboprophylaxis

Fragmin Tolerability

Find out more

Fragmin Guidelines

View guidelines

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No